drugset / Trial / NCT01103310

Radiation Dosimetry, Metabolism, Pharmacokinetics, Safety and Tolerability and PET Imaging With BAY94-9392 in Healthy Volunteers and Patients With Cancer or Inflammation

NCT01103310

Phase 1 Completed 46 enrolled Lantheus Biosciences Ltd.
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

Visual assessment of diagnostic PET/CT (positron emission tomography/computed tomography) images obtained after a single intravenous injection of BAY94-9392 in patients with cancer or inflammation.

Timeline

Start
2010-04
Primary completion
2011-08
Completion
2011-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject 18F-FSPG Diagnostic / imaging agent 300 mbq Intravenous

Indications